Patents by Inventor Wenqing Yao

Wenqing Yao has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • PYRIDO[3,2-D]PYRIMIDINE COMPOUNDS AS IMMUNOMODULATORS
    Publication number: 20210094976
    Abstract: The present disclosure is directed to compounds of Formula (I): which modulate PD-1/PD-L1 protein/protein interaction, compositions, and methods of treating various diseases, including infectious diseases and cancer.
    Type: Application
    Filed: September 29, 2020
    Publication date: April 1, 2021
    Inventors: Jingwei Li, Liangxing Wu, Wenqing Yao
  • Tricyclic heterocyclic compounds as sting activators
    Patent number: 10947227
    Abstract: The present application provides tricyclic heterocyclic compounds that activate the STING pathway to produce interferons, which are useful in the treatment of various diseases including infectious diseases and cancer.
    Type: Grant
    Filed: May 24, 2019
    Date of Patent: March 16, 2021
    Assignee: Incyte Corporation
    Inventors: Liangxing Wu, Neil Lajkiewicz, Yingda Ye, Zhenwu Li, Wenqing Yao
  • Bicyclic heterocycles as FGFR inhibitors
    Patent number: 10947230
    Abstract: The present invention relates to bicyclic heterocycles, and pharmaceutical compositions of the same, that are inhibitors of one or more FGFR enzymes and are useful in the treatment of FGFR-associated diseases such as cancer.
    Type: Grant
    Filed: September 10, 2019
    Date of Patent: March 16, 2021
    Assignees: Incyte Corporation, Incyte Holdings Corporation
    Inventors: Yaping Sun, Wenqing Yao, Liangxing Wu, Meizhong Xu, Ding-Quan Qian, Fenglei Zhang
  • TRIAZOLOPYRIMIDINES AS A2A / A2B INHIBITORS
    Publication number: 20210061809
    Abstract: This application relates to compounds of Formula (I): or pharmaceutically acceptable salts or stereoisomers thereof, which modulate the activity of adenosine receptors, such as subtypes A2A and A2B receptors, and are useful in the treatment of diseases related to the activity of adenosine receptors including, for example, cancer, inflammatory diseases, cardiovascular diseases, and neurodegenerative diseases.
    Type: Application
    Filed: August 25, 2020
    Publication date: March 4, 2021
    Inventors: Heeoon Han, Le Zhao, Wenqing Yao, Xiaozhao Wang
  • Pyrazolopyridine compounds and uses thereof
    Patent number: 10934288
    Abstract: Disclosed are compounds of Formula (I), methods of using the compounds for inhibiting HPK1 activity and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders associated with HPK1 activity such as cancer.
    Type: Grant
    Filed: August 20, 2019
    Date of Patent: March 2, 2021
    Assignee: Incyte Corporation
    Inventors: Oleg Vechorkin, Kai Liu, Alexander Sokolsky, Anlai Wang, Hai Fen Ye, Qinda Ye, Wenqing Yao
  • IMIDAZOLYL PYRIMIDINYLAMINE COMPOUNDS AS CDK2 INHIBITORS
    Publication number: 20210047294
    Abstract: The present application provides imidazolyl pyrimidinylamine inhibitors of cyclin-dependent kinase 2 (CDK2), as well as pharmaceutical compositions thereof, and methods of treating cancer using the same.
    Type: Application
    Filed: August 13, 2020
    Publication date: February 18, 2021
    Inventors: Qinda Ye, Jingwei Li, Ken Mukai, Brandon Smith, Liangxing Wu, Wenqing Yao, Min Ye, Yingnan Chen, Margaret Favata, Yvonne Lo
  • Imidazo[1,2-B][1,2,4]triazines as c-Met inhibitors
    Patent number: 10919901
    Abstract: The present invention relates to imidazo[1,2-b][1,2,4]triazines that are inhibitors of c-Met and are useful in the treatment of c-Met associated diseases including cancer.
    Type: Grant
    Filed: October 4, 2019
    Date of Patent: February 16, 2021
    Assignees: Incyte Holdings Corporation, Incyte Corporation
    Inventors: Jincong Zhuo, Chunhong He, Wenqing Yao
  • CYCLOPROPYLAMINES AS LSD1 INHIBITORS
    Publication number: 20210032244
    Abstract: The present invention is directed to cyclopropylamine derivatives which are LSD1 inhibitors useful in the treatment of diseases such as cancer.
    Type: Application
    Filed: June 9, 2020
    Publication date: February 4, 2021
    Inventors: Liangxing Wu, Joel R. Courter, Chunhong He, Ding-Quan Qian, Bo Shen, Xiaozhao Wang, Wenqing Yao, Fenglei Zhang
  • Heterocyclic compounds as immunomodulators
    Patent number: 10906920
    Abstract: Disclosed are compounds of Formula (I), methods of using the compounds as immunomodulators, and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders such as cancer or infections.
    Type: Grant
    Filed: March 5, 2020
    Date of Patent: February 2, 2021
    Assignee: Incyte Corporation
    Inventors: Liangxing Wu, Kaijiong Xiao, Wenqing Yao
  • CYCLOPROPYLAMINES AS LSD1 INHIBITORS
    Publication number: 20210024487
    Abstract: The present invention is directed to cyclopropylamine derivatives which are LSD1 inhibitors useful in the treatment of diseases such as cancer.
    Type: Application
    Filed: May 1, 2020
    Publication date: January 28, 2021
    Inventors: Liangxing Wu, Joel R. Courter, Chunhong He, Leah C. Konkol, Ding-Quan Qian, Bo Shen, Wenqing Yao, Fenglei Zhang
  • Benzothiazole compounds and uses thereof
    Patent number: 10899755
    Abstract: Disclosed are compounds of Formula (I), methods of using the compounds for inhibiting HPK1 activity and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders associated with HPK1 activity such as cancer.
    Type: Grant
    Filed: August 7, 2019
    Date of Patent: January 26, 2021
    Assignee: Incyte Corporation
    Inventors: Joshua Hummel, Oleg Vechorkin, Alexander Sokolsky, Qinda Ye, Kai Liu, Wenqing Yao
  • HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS
    Publication number: 20210017175
    Abstract: Disclosed are compounds of Formula (I), methods of using the compounds as immunomodulators, and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders such as cancer or infections.
    Type: Application
    Filed: September 25, 2020
    Publication date: January 21, 2021
    Inventors: Zhenwu Li, Liangxing Wu, Wenqing Yao
  • HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS
    Publication number: 20210017164
    Abstract: Disclosed are compounds of Formula (I), methods of using the compounds as immunomodulators, and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders such as cancer or infections.
    Type: Application
    Filed: October 5, 2020
    Publication date: January 21, 2021
    Inventors: Liang Lu, Ding-Quan Qian, Liangxing Wu, Wenqing Yao
  • PYRAZOLYL PYRIMIDINYLAMINE COMPOUNDS AS CDK2 INHIBITORS
    Publication number: 20210017156
    Abstract: The present application provides pyrazolyl pyrimidinylamine inhibitors of cyclin-dependent kinase 2 (CDK2), as well as pharmaceutical compositions thereof, and methods of treating cancer using the same.
    Type: Application
    Filed: March 4, 2020
    Publication date: January 21, 2021
    Inventors: Joshua Hummel, Jingwei Li, Zhenwu Li, Ding-Quan Qian, Liangxing Wu, Kaijiong Xiao, Meizhong Xu, Jeffrey C. Yang, Wenqing Yao, Fenglei Zhang, Min Ye, Yingnan Chen, Margaret Favata, Yvonne Lo
  • BICYCLIC HETEROCYCLES AS FGFR INHIBITORS
    Publication number: 20210009582
    Abstract: The present invention relates to bicyclic heterocycles, and pharmaceutical compositions of the same, that are inhibitors of the FGFR3 enzyme and are useful in the treatment of FGFR3-associated diseases such as cancer.
    Type: Application
    Filed: July 8, 2020
    Publication date: January 14, 2021
    Inventors: Oleg Vechorkin, Chao Qi, Minh Nguyen, Anlai Wang, Wenqing Yao
  • HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS
    Publication number: 20210002276
    Abstract: Disclosed are compounds of Formula (I), methods of using the compounds as immunomodulators, and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders such as cancer or infections.
    Type: Application
    Filed: September 15, 2020
    Publication date: January 7, 2021
    Inventors: Liangxing Wu, Bo Shen, Meizhong Xu, Wenqing Yao
  • INDAZOLE COMPOUNDS AND USES THEREOF
    Publication number: 20210002288
    Abstract: Disclosed are compounds of Formula (I), methods of using the compounds for inhibiting HPK1 activity and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders associated with HPK1 activity such as cancer.
    Type: Application
    Filed: July 21, 2020
    Publication date: January 7, 2021
    Inventors: Alexander Sokolsky, Oleg Vechorkin, Anlai Wang, Qinda Ye, Wenqing Yao
  • HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS
    Publication number: 20200407357
    Abstract: Disclosed are compounds of Formula (I?), methods of using the compounds as immunomodulators, and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders such as cancer or infections.
    Type: Application
    Filed: September 11, 2020
    Publication date: December 31, 2020
    Inventors: Neil Lajkiewicz, Liangxing Wu, Wenqing Yao
  • THIAZOLECARBOXAMIDES AND PYRIDINECARBOXAMIDE COMPOUNDS USEFUL AS PIM KINASE INHIBITORS
    Publication number: 20200405702
    Abstract: The present disclosure describes thiazole and pyridine carboxamide derivatives, their compositions and methods of use. The compounds inhibit the activity of the Pim kinases and are useful in the treatment of diseases related to the activity of Pim kinases including, e.g., cancer and other diseases.
    Type: Application
    Filed: September 16, 2020
    Publication date: December 31, 2020
    Inventors: Chu-Biao Xue, Yun-Long Li, Hao Feng, Jun Pan, Anlai Wang, Ke Zhang, Wenqing Yao, Fenglei Zhang, Jincong Zhuo
  • Heteroaryl amide compounds as sting activators
    Patent number: 10875872
    Abstract: The present application provides heteroaryl amide compounds that activate the STING pathway to produce interferons, which are useful in the treatment of various diseases including infectious diseases and cancer.
    Type: Grant
    Filed: July 31, 2019
    Date of Patent: December 29, 2020
    Assignee: Incyte Corporation
    Inventors: Liangxing Wu, Neil Lajkiewicz, Wenqing Yao